Key points are not available for this paper at this time.
Key Points Patients with t-MDS are underrepresented in clinical trials when taking into account the prevalence of such patients. Eligibility criteria and sponsorship type may contribute to t-MDS patient exclusion.
Borate et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: